Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#412 of 589

Thomas Smith

Leerink Partners · Equity Research Analyst
ProvisionalRating since 2021No new ratings since Oct 2025

Analyst rating accuracy & track record

Thomas Smith is an equity research analyst at Leerink Partners. Quantellect has scored 26 of their stock calls across 16 companies. Their picks beat their sector 41% of the time over the next 12 months, and their price targets were reached 29% of the time within a year.

Win % vs sector
41%
PT Hit % (12mo)
29%
Avg sector-excess
−10.6%
Scored calls
26
Tickers
16
Tier
Provisional

Track record

Quantellect has scored 26 of Thomas Smith's stock calls across 16 companies, dating back to 2021. Their rated stocks beat their own sector 41% of the time over the next 12 months. On a typical call, a Smith pick returned −10.6% more than its sector over the following year.

Of the scored calls, 26 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
VKTXViking Therapeutics Inc
Buy$118.00Oct 2025−52.9%Miss
VKTXViking Therapeutics Inc
Buy$118.00Oct 2025−52.9%Miss
SABSSAB Biotherapeutics Inc
Buy—Oct 2025−29.6%—
IRONDisc Medicine Inc.
Buy$100.00Oct 2025−31.8%Miss
ACRSAclaris Therapeutics Inc
Buy$7.00Oct 2025+44.7%Miss
ABVXAbivax SA American Depositary Shares
Buy$115.00Oct 2025−19.3%Hit
MLTXMoonLake Immunotherapeutics
Buy$14.00Oct 2025+36.7%Hit
ARGXargenx NV ADR
Buy$780.00Sep 2025+12.2%Hit
CLDXCelldex Therapeutics Inc
Buy—Aug 2025+70.2%—
MDGLMadrigal Pharmaceuticals Inc
Buy—Aug 2025+8.5%—
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$26.00Aug 2025+27.4%Miss
ELDNEledon Pharmaceuticals Inc
Buy$8.00Aug 2025+13.4%Miss
ELDNEledon Pharmaceuticals Inc
Buy$8.00Aug 2025+13.4%Miss
RNACCartesian Therapeutics Inc.
Buy$39.00Aug 2025−54.0%Miss
ACRSAclaris Therapeutics Inc
Buy$7.00Nov 2024−46.4%Miss
QTTBQ32 Bio Inc
Buy$54.00May 2024−85.7%Miss
EQEquillium Inc
Buy$7.00Feb 2023+25.3%Miss
CNTBConnect Biopharma Holdings Ltd
Buy$7.00Feb 2023−13.4%Miss
EQEquillium Inc
Buy$12.00Sep 2022−66.8%Miss
PRTCPureTech Health PLC
Buy$70.00Aug 2022−19.7%Miss
PRTCPureTech Health PLC
Buy$66.00Jun 2022+30.4%Miss
CNTBConnect Biopharma Holdings Ltd
Buy$9.00May 2022+59.5%Miss
PRTCPureTech Health PLC
Buy$70.00Jan 2022−20.1%Miss
CNTBConnect Biopharma Holdings Ltd
Buy$22.00Jan 2022−84.1%Miss
EQEquillium Inc
Buy$14.00Jan 2022−67.7%Miss
Prev1
Go to

Thomas Smith: analyst track record FAQ

Is Thomas Smith a good stock analyst?

Yes, by track record. Thomas Smith ranks number 412 of 589 of the analysts Quantellect scores, with an Analyst Score of 18 out of 100. Past results do not guarantee future ones.

What is Thomas Smith's win rate?

Thomas Smith's win rate is 41%. Across 26 scored calls, their rated stocks beat their sector 41% of the time over the next 12 months. On a typical call they returned −10.6% more than the sector.

What stocks and sectors does Thomas Smith cover?

Thomas Smith covers 16 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Thomas Smith's price targets accurate?

Thomas Smith's price targets are reached within 12 months 29% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Thomas Smith's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Thomas Smith rank among Wall Street analysts?

Thomas Smith ranks number 412 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.